Top 10 Pharma R&D Budgets in 2025: Strategic Spending Cuts, Obesity Boom, and Pipeline Shifts
📌 Key Takeaways: 2025 Pharma R&D Landscape
- Widespread Budget Tightening: 6 out of the top 10 drugmakers reduced their R&D spending in 2025 compared to 2024, with cuts ranging up to 28.9%.
- Merck Retains Top Spot: Despite a 12% drop in spending ($15.79B), Merck led all competitors, driven by continued Keytruda protection strategy and clinical expansion.
- Eli Lilly’s Metoric Surge: Fueled by massive weight-loss sales (tirzepatide), Eli Lilly boosted its R&D budget by 21.4% to $13.34B, climbing two spots up the ladder.
- Heavy M&A Offsets Internal Cuts: Major players like Johnson & Johnson leaned into high-value acquisitions (e.g., $14.6B buyout of Intra-Cellular) while trimming internal trial pipelines.
The pharmaceutical industry experienced significant volatility in 2025. Between shifting regulatory policies, National Institutes of Health (NIH) grant shifts, and FDA trial scrutiny, major biopharmaceutical firms were forced to re-examine their research outlays.
| Global biopharma leaders reallocated capital into high-velocity clinical programs and targeted M&A in 2025. |
While the top 10 companies remained identical to the previous year’s list, their strategy shifted dramatically. Instead of rapid budget growth, most pharma giants exercised strict spending discipline or redirected capital toward high-yield therapeutic areas like metabolic/obesity care, targeted oncology, and immunology.
2025 Big Pharma R&D Spending at a Glance
| Rank | Company | 2025 R&D Budget | YoY Change | 2025 Revenue | R&D % of Revenue |
|---|---|---|---|---|---|
| 1 | Merck & Co. | $15.79 B | -12.0% | $65.01 B | 24.3% |
| 2 | Roche | $14.73 B (CHF 12.24B) | -6.0% | $76.24 B | 19.3% |
| 3 | Johnson & Johnson | $14.66 B | -14.9% | $94.20 B | 15.6% |
| 4 | AstraZeneca | $14.23 B | +5.0% | $58.74 B | 24.2% |
| 5 | Eli Lilly | $13.34 B | +21.4% | $65.18 B | 20.5% |
| 6 | Novartis | $11.20 B | +12.0% | $54.50 B | 20.6% |
| 7 | Pfizer | $10.44 B | -4.0% | $62.57 B | 16.7% |
| 8 | Bristol Myers Squibb | $9.95 B | -11.0% | $48.20 B | 20.6% |
| 9 | AbbVie | $9.10 B | -28.9% | $61.16 B | 14.9% |
| 10 | Sanofi | $8.85 B (€7.84B) | +6.0% | $43.60 B | 18.0% |
Detailed Analysis: Top 10 Pharma R&D Spenders
1. Merck & Co. — $15.79 Billion (-12%)
R&D Intensity: 24.3% of revenue ($65.01B)
Despite reducing business development expenditures compared to 2024, Merck retained the #1 ranking. The core Merck Research Laboratories (MRL) unit actually increased baseline spending to $10.8 billion. Major investments included Phase 3 trials for oral PCSK9 inhibitor enlicitide decanoate and HIV combination therapies, all aimed at protecting revenue ahead of Keytruda's upcoming patent expiration.
2. Roche — $14.73 Billion / CHF 12.24B (-6%)
R&D Intensity: 19.3% of revenue ($76.24B)
Roche advanced to the second spot globally despite a mild overall budget trim. Oncology dominated spending, highlighted by KRAS inhibitor divarasib in non-small cell lung cancer and SERD candidate giredestrant in breast cancer. Roche also amplified its metabolic ambitions, accelerating dual GLP-1/GIP candidate CT-388 following its Carmot acquisition.
3. Johnson & Johnson — $14.66 Billion (-14.9%)
R&D Intensity: 15.6% of revenue ($94.20B)
J&J slipped to 3rd place as internal pipeline restructuring and trial discontinuation in anticoagulants and depression triggered a nearly 15% spend reduction. However, external M&A remained aggressive, marked by a $14.6 billion buyout of Intra-Cellular Therapies and a $3 billion acquisition of Halda Therapeutics.
4. AstraZeneca — $14.23 Billion (+5%)
R&D Intensity: 24.2% of revenue ($58.74B)
AstraZeneca devoted nearly a quarter of its entire top-line revenue to research. Despite minor late-stage trial setbacks in amyloidosis, the British drugmaker maintained steady growth across oncology, rare disease, and cardiovascular platforms.
5. Eli Lilly — $13.34 Billion (+21.4%)
R&D Intensity: 20.5% of revenue ($65.18B)
Eli Lilly was the standout performer of 2025, jumping two ranks up the list. Commercial momentum from GLP-1 blockbusters Zepbound and Mounjaro (tirzepatide) enabled Lilly to reinvest aggressively into oral metabolic therapies like orforglipron, AI-driven discovery platforms, and gene therapy acquisitions.
6. Novartis — $11.20 Billion (+12%)
R&D Intensity: 20.6% of revenue ($54.50B)
Novartis rebounded into solid double-digit growth, expanding funding for targeted radioligands, cardiovascular therapies, and neuroscience pipeline additions following the integration of MorphoSys and Avidity assets.
7. Pfizer — $10.44 Billion (-4%)
R&D Intensity: 16.7% of revenue ($62.57B)
Pfizer continued its post-COVID operational rebalancing, prioritizing high-conviction oncology programs (boosted by Seagen capabilities) and mRNA platforms while curbing lower-priority clinical trials.
8. Bristol Myers Squibb — $9.95 Billion (-11%)
R&D Intensity: 20.6% of revenue ($48.20B)
BMS kept its R&D spend close to 20% of revenue, but trimmed overall outlays by 11% as part of broader operational efficiencies and pipeline optimization preceding patent expirations on legacy oncology brands.
9. AbbVie — $9.10 Billion (-28.9%)
R&D Intensity: 14.9% of revenue ($61.16B)
AbbVie recorded the largest percentage reduction in the top 10 (-28.9%). This represented a planned recalibration following its massive 66% R&D surge in 2024, focusing capital heavily toward oncology and immunology hubs.
10. Sanofi — $8.85 Billion / €7.84B (+6%)
R&D Intensity: 18.0% of revenue ($43.60B)
Sanofi rounded out the top 10 with a modest 6% spending increase, reflecting its ongoing pivot toward pure-play biopharma innovation and immunology assets.
Frequently Asked Questions (FAQ)
Which pharma company had the largest R&D budget in 2025?
Merck & Co. maintained the top spot in 2025 with an R&D budget of $15.79 billion, representing 24.3% of its total revenue.
Why did many pharmaceutical companies cut R&D spending in 2025?
Most major drugmakers trimmed R&D budgets due to regulatory scrutiny, federal grant realignments, trial portfolio rationalization, and a pivot toward strategic M&A acquisitions over early-stage internal research.
Which company saw the fastest growth in R&D investment?
Eli Lilly achieved the highest growth among top-tier spenders, increasing its R&D budget by 21.4% to $13.34 billion, driven by blockbuster sales in the obesity and diabetes categories.
Comments